We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$60.9M
Cap. Flow
+$27.1M
Cap. Flow %
5.19%
Top 10 Hldgs %
45.15%
Holding
120
New
43
Increased
21
Reduced
16
Closed
38

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$22.2M
2
BHVN icon
Biohaven
BHVN
+$17.4M
3
MBX
MBX Biosciences
MBX
+$14.3M
4
CGON icon
CG Oncology
CGON
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.9M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$28.9M
2
ACLX
Arcellx
ACLX
+$21.7M
3
TWST icon
Twist Bioscience
TWST
+$21.3M
4
TERN
Terns Pharmaceuticals
TERN
+$17.6M
5
ROIV icon
Roivant Sciences
ROIV
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Financials 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
26
Tyra Biosciences
TYRA
$1.91B
$7.4M 1.42%
+193,177
New +$6.25M
DNTH icon
27
Dianthus Therapeutics
DNTH
$5.77B
$7.18M 1.37%
85,502
+6,218
+8% +$360K
CELC icon
28
Celcuity
CELC
$4.31B
$6.86M 1.31%
60,062
-58,271
-49% -$6.35M
DFTX
29
Definium Therapeutics
DFTX
$5.88B
$6.15M 1.18%
+325,483
New +$5.52M
BIOA
30
BioAge Labs
BIOA
$1.01B
$5.92M 1.13%
+338,654
New +$6.52M
NAMS icon
31
NewAmsterdam Pharma
NAMS
$3.7B
$5.78M 1.11%
180,658
+107,552
+147% +$3.5M
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.38B
$5.4M 1.03%
+242,566
New +$5.8M
ASMB icon
33
Assembly Biosciences
ASMB
$531M
$5.15M 0.99%
185,435
+28,707
+18% +$819K
ALMS
34
Alumis Inc
ALMS
$3.65B
$5.06M 0.97%
+229,566
New +$5.74M
NRIX icon
35
Nurix Therapeutics
NRIX
$2.4B
$4.89M 0.94%
+315,226
New +$5.23M
ZURA icon
36
Zura Bio
ZURA
$518M
$4.48M 0.86%
+753,520
New +$4.55M
EVMN
37
Evommune Inc
EVMN
$437M
$4.39M 0.84%
193,777
+125,581
+184% +$2.84M
TNGX icon
38
Tango Therapeutics
TNGX
$4.65B
$4.2M 0.8%
+200,919
New +$2.8M
FTH
39
Faeth Therapeutics
FTH
$667M
$4.19M 0.8%
+132,873
New +$2.65M
RLMD icon
40
Relmada Therapeutics
RLMD
$550M
$4.16M 0.8%
+597,409
New +$2.83M
ERAS icon
41
Erasca
ERAS
$6.65B
$3.88M 0.74%
+239,861
New +$2.83M
JNJ icon
42
Johnson & Johnson
JNJ
$609B
$3.77M 0.72%
15,415
-19,585
-56% -$4.56M
XFOR icon
43
X4 Pharmaceuticals
XFOR
$360M
$3.51M 0.67%
850,742
-47,723
-5% -$179K
PCVX icon
44
Vaxcyte
PCVX
$8.12B
$3.43M 0.66%
+59,061
New +$3.21M
WHWK
45
Whitehawk Therapeutics
WHWK
$192M
$3.24M 0.62%
939,369
-519,438
-36% -$1.63M
HLXC
46
Helix Acquisition Corp III
HLXC
$233M
$3.1M 0.59%
+305,028
New +$3.12M
TENX icon
47
Tenax Therapeutics
TENX
$420M
$3.02M 0.58%
+188,700
New +$2.55M
ALKS icon
48
Alkermes
ALKS
$8.79B
$2.85M 0.54%
+80,492
New +$2.5M
PHVS icon
49
Pharvaris
PHVS
$2.44B
$2.45M 0.47%
86,637
+28,248
+48% +$754K
IVVD icon
50
Invivyd
IVVD
$219M
$2.44M 0.47%
1,874,546
+884,724
+89% +$1.62M
1
2
3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Stempoint Capital held 120 positions worth $522M, down 10% from $583M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Stempoint Capital deployed $27.1M of net new capital in Q1 2026, opening 43 new positions and adding to 21 existing holdings. Its largest new stake was Biohaven: 1,594,491 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $21.3M trimmed.

  • Stempoint Capital's largest Q1 2026 buy was Biohaven: 1,594,491 shares worth $13.5M.
  • Stempoint Capital added most to Revolution Medicines in Q1 2026, an estimated $22.2M increase.
  • Stempoint Capital's biggest Q1 2026 reduction was Twist Bioscience, cutting an estimated $21.3M.
  • Stempoint Capital fully exited Centessa Pharmaceuticals in Q1 2026, selling an estimated $28.9M.
  • Stempoint Capital's ten largest holdings make up 45% of its $522M portfolio in Q1 2026.
  • Stempoint Capital opened 43 new positions and closed 38 in Q1 2026.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $522M.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.